Skip to main content
. 2024 May 9;42(17):2080–2093. doi: 10.1200/JCO.23.01636

FIG 4.

FIG 4.

Kaplan-Meier estimates of OS. (A) Patients with LAG-3 expression ≥1%; (B) patients with LAG-3 expression <1%; and (C) all randomly assigned patients. Symbols represent censored observations. Chemo, chemotherapy; HR, hazard ratio; LAG-3, lymphocyte-activation gene 3; NE, not estimable; NIVO, nivolumab; OS, overall survival; RELA, relatlimab.